Therefore, the registration provisions should require manufacturers and importers to
generate data on the substances they manufacture or import, to use these data to assess the
risks related to these substances and to develop and recommend appropriate risk
management measures. To ensure that they actually meet these obligations, as well as for
transparency reasons, registration should require them to submit a dossier containing all
this information to the Agency. Registered substances should be allowed to circulate on the
internal market.
(20) The evaluation provisions should provide for follow-up to registration, by allowing for
checks on whether registrations are in compliance with the requirements of this Regulation
and if necessary by allowing for generation of more information on the properties of
substances. If the Agency in cooperation with the Member States considers that there are
grounds for considering that a substance constitutes a risk to human health or the
environment, the Agency should, after having included the substance in the Community
rolling action plan for substance evaluation, relying on the competent authorities of
Member States, ensure that this substance is evaluated.
(21) Although the information yielded on substances through evaluation should be used in the
first place by manufacturers and importers to manage the risks related to their substances,
it may also be used to initiate the authorisation or restrictions procedures under this
Regulation or risk management procedures under other Community legislation. Therefore
it should be ensured that this information is available to the competent authorities and may
be used by them for the purpose of such procedures.